Spots Global Cancer Trial Database for bibw 2992
Every month we try and update this database with for bibw 2992 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma | NCT00727506 | Glioma | BIBW 2992 TMZ BIBW 2992 plus ... | 18 Years - | Boehringer Ingelheim | |
| LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment | NCT01125566 | Breast Neoplasm... | BIBW 2992 trastuzumab vinorelbine vinorelbine | 18 Years - | Boehringer Ingelheim | |
| Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours. | NCT00998296 | Neoplasms | BIBW 2992 BIBF 1120 | 18 Years - | Boehringer Ingelheim | |
| BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation | NCT00949650 | Carcinoma, Non-... Adenocarcinoma | Pemetrexed BIBW 2992 Cisplatin | 18 Years - | Boehringer Ingelheim | |
| Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors | NCT02171637 | Neoplasms | BIBW 2992 | 18 Years - | Boehringer Ingelheim | |
| BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC) | NCT01121393 | Carcinoma, Non-... Adenocarcinoma | Gemcitabine+Cis... BIBW 2992 | 18 Years - | Boehringer Ingelheim | |
| BIBW 2992 as add-on to Gem/Cis in Advanced Biliary Tract Cancer | NCT01679405 | Metastatic Dise... | BIBW 2992 | 18 Years - | Johannes Gutenberg University Mainz | |
| Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours | NCT00809133 | Neoplasms | Paclitaxel Carboplatin BIBW 2992 Paclitaxel BIBW2992 Paclitaxel Carboplatin Bevacizumab BIBW 2992 BIBW 2992 | 18 Years - | Boehringer Ingelheim | |
| BIBW 2992 as add-on to Gem/Cis in Advanced Biliary Tract Cancer | NCT01679405 | Metastatic Dise... | BIBW 2992 | 18 Years - | Johannes Gutenberg University Mainz | |
| BIBW2992 (Afatinib) in Advanced (EGFR-FISH +) NSCLC (Non Small Cell Lung Cancer) Patients | NCT00796549 | Carcinoma, Non-... | BiBW 2992 | 18 Years - | Boehringer Ingelheim | |
| BIBW 2992 (Afatinib) in Head & Neck Cancer | NCT00514943 | Head and Neck N... Carcinoma, Squa... | BIBW 2992 Cetuximab | 18 Years - | Boehringer Ingelheim | |
| Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib | NCT00993499 | Carcinoma, Non-... | BIBW 2992 Sirolimus (rapa... | 18 Years - | Boehringer Ingelheim | |
| BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1) | NCT00656136 | Carcinoma, Non-... | placebo BIBW 2992 | 18 Years - | Boehringer Ingelheim | |
| BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation | NCT00949650 | Carcinoma, Non-... Adenocarcinoma | Pemetrexed BIBW 2992 Cisplatin | 18 Years - | Boehringer Ingelheim | |
| Tetracycline as a Prophylaxis for Rash in Patients With NSCLC Receiving Treatment With BIBW2992 (Afatinib) | NCT01880515 | Skin Rash Lung Cancer | Tetracycline | 18 Years - | Instituto Nacional de Cancerologia de Mexico | |
| LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib | NCT01085136 | Carcinoma, Non-... | Investigator´s ... BIBW 2992 | 18 Years - | Boehringer Ingelheim | |
| BIBW2992 (Afatinib) in Advanced (EGFR-FISH +) NSCLC (Non Small Cell Lung Cancer) Patients | NCT00796549 | Carcinoma, Non-... | BiBW 2992 | 18 Years - | Boehringer Ingelheim | |
| BIBW 2992 in Patients With Advanced Solid Tumors | NCT02171650 | Neoplasms | BIBW 2992 | 18 Years - | Boehringer Ingelheim | |
| An Open Label Phase II Trial of BIBW 2992 in Patients With HER2-negative Metastatic Breast Cancer | NCT00425854 | Breast Neoplasm... | BIBW 2992 | 18 Years - | Boehringer Ingelheim | |
| Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non-small Cell Lung Cancer | NCT01542437 | Non-Small Cell ... EGFR HER-2 | BIBW 2992 | 18 Years - 90 Years | Instituto Nacional de Cancerologia de Mexico | |
| Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours | NCT00809133 | Neoplasms | Paclitaxel Carboplatin BIBW 2992 Paclitaxel BIBW2992 Paclitaxel Carboplatin Bevacizumab BIBW 2992 BIBW 2992 | 18 Years - | Boehringer Ingelheim | |
| LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations | NCT00525148 | Carcinoma, Non-... | BIBW 2992 | 18 Years - 99 Years | Boehringer Ingelheim | |
| Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy | NCT00431067 | Breast Neoplasm... | BIBW 2992 | 18 Years - | Boehringer Ingelheim | |
| Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors | NCT00730821 | Neoplasms | BIBW 2992 BIBF 1120 | 18 Years - 75 Years | Boehringer Ingelheim | |
| BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1) | NCT00656136 | Carcinoma, Non-... | placebo BIBW 2992 | 18 Years - | Boehringer Ingelheim | |
| The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting | NCT02271906 | Lung Cancer | BIBW 2992 | 18 Years - | M.D. Anderson Cancer Center | |
| LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib | NCT01085136 | Carcinoma, Non-... | Investigator´s ... BIBW 2992 | 18 Years - | Boehringer Ingelheim | |
| Understanding Mechanisms of Acquired Resistance to BIBW2992 | NCT01074177 | Non-small Cell ... EGFR Mutations | BIBW 2992 | 18 Years - | Massachusetts General Hospital | |
| Study to Determine the Maximum Tolerated Dose of BIBW 2992 (Afatinib) When Combined With Cisplatin/Paclitaxel or Cisplatin/5-FU in Patients With Advanced Solid Tumours | NCT00716417 | Neoplasms | BIBW 2992 BIBW 2992 | 18 Years - | Boehringer Ingelheim | |
| Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer. | NCT00950742 | Breast Neoplasm... | Trastuzumab BIBW 2992 | 18 Years - | Boehringer Ingelheim | |
| 6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab | NCT00826267 | Breast Neoplasm... | lapatinib BIBW 2992 trastuzumab | 18 Years - | Boehringer Ingelheim | |
| Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy | NCT01594177 | Unilateral HER2... | Afatinib Trastuzumab Paclitaxel Epirubicin Cyclophosphamid... | 18 Years - | German Breast Group | |
| BIBW 2992 (Afatinib) in Head & Neck Cancer | NCT00514943 | Head and Neck N... Carcinoma, Squa... | BIBW 2992 Cetuximab | 18 Years - | Boehringer Ingelheim | |
| Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid Tumors | NCT02171741 | Neoplasms | BIBW 2992 Docetaxel | 18 Years - | Boehringer Ingelheim | |
| BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC) | NCT01121393 | Carcinoma, Non-... Adenocarcinoma | Gemcitabine+Cis... BIBW 2992 | 18 Years - | Boehringer Ingelheim | |
| A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer | NCT01152437 | Colorectal Neop... | BIBW 2992 Cetuximab | 18 Years - | Boehringer Ingelheim | |
| Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy | NCT00431067 | Breast Neoplasm... | BIBW 2992 | 18 Years - | Boehringer Ingelheim | |
| 6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab | NCT00826267 | Breast Neoplasm... | lapatinib BIBW 2992 trastuzumab | 18 Years - | Boehringer Ingelheim | |
| Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy | NCT00431067 | Breast Neoplasm... | BIBW 2992 | 18 Years - | Boehringer Ingelheim | |
| BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid Tumors | NCT02171676 | Neoplasms | Docetaxel BIBW 2992 | 18 Years - | Boehringer Ingelheim | |
| 6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab | NCT00826267 | Breast Neoplasm... | lapatinib BIBW 2992 trastuzumab | 18 Years - | Boehringer Ingelheim | |
| BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC | NCT01156545 | Non-small Cell ... | BIBW 2992 simvastatin | 18 Years - | National Cancer Center, Korea | |
| Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer | NCT01090011 | Carcinoma, Non-... | Cetuximab Cetuximab BIBW 2992 BIBW 2992 | 18 Years - | Boehringer Ingelheim | |
| Dose Escalation Study of Continuous Once-daily Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors | NCT02171728 | Neoplasms | BIBW 2992 | 18 Years - | Boehringer Ingelheim | |
| A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer | NCT00706628 | Prostatic Neopl... | BIBF 1120 BIBW 2992 Sequential BIBF... | 18 Years - | Boehringer Ingelheim | |
| Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours. | NCT00998296 | Neoplasms | BIBW 2992 BIBF 1120 | 18 Years - | Boehringer Ingelheim | |
| Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors | NCT00730821 | Neoplasms | BIBW 2992 BIBF 1120 | 18 Years - 75 Years | Boehringer Ingelheim |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
